逾20亿元研发投入“打水漂”,百济神州一款在研抗肿瘤新药折戟

新京报
10 Apr

继被诺华“退货”后,百济神州自己也放弃了TIGIT抑制剂欧司珀利单抗。据百济神州有限公司(简称:百济神州)官网最新消息显示,终止抗TIGIT抗体欧司珀利单抗(BGB-A1217)作为肺癌潜在治疗方法的临床开发项目。截至2024年上半年,百济神州在欧司珀利单抗项目中累计投入为20.9亿元。  因可通过抑制相关信号传导促进T细胞增殖和攻击肿瘤细胞的能力,TIGIT单抗一度被视为下一代癌症免疫治疗的靶点...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10